Fusion Antibodies
Belfast
About Fusion Antibodies
Fusion Antibodies specializes in production of high quality humanized monoclonal antibodies and antibody engineering projects. The company has the knowledge and expertise to build and deliver a bespoke package of the services people need to achieve outstanding results. Using the technology, the sequences of the antibody variable domains which determine its binding specificity are incorporated into human donor sequences creating a panel of full length humanized antibodies for expression. Fully humanized monoclonal antibodies are an essential step in the progression of your drug to the clinic and the in-house expertise at Fusion Antibodies ensures its success. All of Fusion Antibodies services are offered on a fee-for-service basis and is flexible on the elements of the project people would like included. Fusion Antibodies have strong links with the several partners around the globe, allowing it to deliver a complete bespoke package, at an incredible price. Fusion Antibodies was founded on 2001 and is based in Belfast, United Kingdom.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $5.1M
- Funding stage: IPO
- Last round: Post-IPO Equity (Feb 2024)
- Ticker: lse:FAB
- Website: fusionantibodies.com
- Phone: +44 28 9043 2800
Industries & Categories
Biotechnology, Clinical Trials, Health Diagnostics, Manufacturing, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/fusion-antibodies-167051 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.